RTS,S/AS01 malaria vaccine (Mosquirix®): a profile of its use

<p>  </p> <p><strong>Declarations</strong></p> <p><strong>Funding</strong> The preparation of this review was not supported by any external funding.</p> <p><strong>Authorship and Conflict of interest</strong> Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</p> <p><strong>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability</strong> not applicable</p> <p>Additional information about this Adis Drug Review can be found <a href="https://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews" target="_blank">here</a></p> <p><strong>Abstract</strong></p> <p>RTS,S/AS01 (Mosquirix®), the first malaria vaccine, is indicated for the active immunisation of children against malaria caused Plasmodium falciparum. In a phase 3 trial, RTS,S/AS01 showed efficacy against P. falciparum malaria, with an acceptable safety and tolerability profile in children aged 6 weeks to 17 months. The efficacy was greater in children aged 5–17 months than in infants aged 6–12 weeks. In another phase 3 trial, RTS,S/AS01 was noninferior to chemoprevention in preventing seasonal malaria in children. WHO recommends a 4-dose schedule of RTS,S/AS01 for the prevention of P. falciparum malaria in children from 5 months of age living in African regions with moderate to high malaria transmission, with an optional 5-dose schedule for seasonal malaria. Preliminary results from large pilot studies in Africa show that RTS,S/AS01 substantially reduces malaria episodes, increases equity in access to malaria prevention, is highly cost effective and can be delivered through the routine national immunization programmes.</p> <p>© Springer Nature Switzerland AG 2022</p>